Optiver Holding B.V. lowered its holdings in Innate Pharma S.A. (NASDAQ:IPHA – Free Report) by 63.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,796 shares of the company’s stock after selling 142,301 shares during the period. Optiver Holding B.V. owned approximately 0.10% of Innate Pharma worth $257,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the business. Balyasny Asset Management LLC purchased a new position in shares of Innate Pharma in the third quarter valued at $32,000. Jane Street Group LLC boosted its stake in shares of Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock valued at $127,000 after purchasing an additional 23,012 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Innate Pharma in the second quarter valued at $133,000. Millennium Management LLC boosted its stake in shares of Innate Pharma by 389.8% in the fourth quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock valued at $267,000 after purchasing an additional 57,050 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Innate Pharma by 27.4% in the first quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock valued at $1,695,000 after purchasing an additional 108,335 shares during the period. Institutional investors and hedge funds own 0.29% of the company’s stock.
Innate Pharma Trading Up 2.4 %
NASDAQ IPHA opened at $2.51 on Tuesday. Innate Pharma S.A. has a 12 month low of $1.81 and a 12 month high of $3.97. The company’s fifty day moving average price is $2.52 and its two-hundred day moving average price is $2.85.
Analysts Set New Price Targets
About Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
- Five stocks we like better than Innate Pharma
- What Are Dividend Champions? How to Invest in the Champions
- The only two airline stocks worth buying: One is a Goldman pick
- The 3 Best Fintech Stocks to Buy Now
- Ride the momentum: Apparel stocks soaring at 52-week highs
- How to Invest in Semiconductors
- Safeguard your portfolio with these three bargain stocks
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.